DRD5
Dopamine receptor D5
As of the edition of 20 October 2026, DRD5 (dopamine receptor D5, UniProt P21918) has 5 drugs tested at it and 8 companies on the list, 1 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P21918
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 1
- Disease areas
- Nervous system; Mental health; Chemically induced; Inherited and neonatal; Ear, nose and throat; Nutrition and metabolism; Pregnancy and women's health; Urinary and reproductive
- Registered trials of its drugs
- 38
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Stopped | 1 |
| Withdrawn from market | 1 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Tavapadon | Stopped | Phase 3 | none listed |
| Pergolide | Withdrawn from market | Phase 4 | none listed |
| Pimozide | Marketed | Phase 4 | none listed |
| Ergoloid | Marketed | Phase 2 | none listed |
| Amoxapine | Marketed | No phase stated | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 2 |
| Engaged | 1 |
| Undetermined | 4 |
| Total on the list | 8 |
| Company | Route |
|---|---|
| Bausch Health | Route A |
| Pfizer | Route B |
| Novartis | Route B |
The other 5 companies at DRD5
In the product8 companies in all; 5 are not named here, and no score is.
See the 8 companies at DRD5, ranked, with the facts behind eachRequest access. Nothing is shown until you do.